Why the study?
Biomarkers are not routinely recommended by guidelines for AF management despite evidence that cardiac-specific troponin may be associated with incident and recurrent AF and its complications.
This review highlights the potential utility of cardiac troponin as a biomarker for predicting incident and recurrent atrial fibrillation and its complications, suggesting a role in clinical management.
May inform AF prognosis; leaves open routine adoption until prospective trials confirm utility.
Atrial fibrillation (AF) is the most common sustained arrhythmia, and its prevalence rate is expected to be doubled over the next decades. Despite the wide use of biomarkers in the management of different cardiac diseases such as myocardial infarction and heart failure, utilization of biomarkers in AF management is not routinely recommended by current guidelines. There is also growing evidence that higher levels of cardiac-specific troponin, as an intracellular protein involved in cardiomyocyte contraction, may be associated with the risk of incident and recurrent AF and its complications. In the present paper, we review the association between troponin and AF and propose clinical suggestions for use of troponin in the management of AF patients.
No takes yet. Share an insight, caveat, or question.
Shamloo et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: